Moreover, GATA2 and MEIS1 knockdown in the leukemic cell lines K562 and Kasumi-1 reduced the frequency of CFU-Cs, verifying that GATA2 and MEIS1 could be potential therapeutic targets for ASXL1 mutation–associated myeloid malignancies. This evidence concerns the gene ASXL1 and myeloid neoplasm.